Unlabelled: Pediatric asthma is a common condition, and its exacerbations can be associated with significant morbidity and mortality. The role of nebulised magnesium as adjunct therapy for children with asthma exacerbations is still unclear. To compare clinical and functional outcomes for children with asthma exacerbation taking either nebulised magnesium sulfate added to standard medical therapy (SMT) versus SMT alone. PubMed, Embase, and Cochrane Library were systematically searched for randomised clinical trials (RCT) comparing the use of SMT with vs. without nebulised magnesium. The outcomes were respiratory rate, heart rate, % predicted peak expiratory flow rate (PEFR), % predicted forced expiratory volume (FEV1), peripheral O saturation, asthma severity scores, and need for intravenous (IV) bronchodilator use. Twelve RCTs and 2484 children were included. Mean age was 5.6 (range 2-17) years old, mean baseline % predicted FEV1 was 69.6%, and 28.66% patients were male. Children treated with magnesium had a significantly higher % predicted PEFR (mean difference [MD] 5.33%; 95% confidence interval [CI] 4.75 to 5.90%; p < 0.01). Respiratory rate was significantly lower in the magnesium group (MD -0.70 respirations per minute; 95% CI -1.24 to -0.15; p < 0.01). Need for IV bronchodilators, % predicted FEV1, heart rate, asthma severity scores, and O saturation were not significantly different between groups.
Conclusion: In children with asthma exacerbation, treatment with nebulised magnesium and SMT was associated with a statistically significant, but small improvement in predicted PEFR and respiratory rate, as compared with SMT alone.
What Is Known: • Magnesium sulfate has bronchodilating properties and aids in the treatment of asthma exacerbation when administered intravenously. • There is no significant evidence of benefit of nebulised magnesium as an adjunct therapy to the standard medical treatment for children with asthma exacerbations.
What Is New: • Our study suggests nebulised magnesium sulfate may have a statistically significant, but small benefit in respiratory rate and peak expiratory flow rate. The addition of nebulised magnesium does not seem to increase adverse events.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00431-024-05517-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of lubricants type and particle size on the rheological properties and aerosolization behavior of dry powder inhalers.
Int J Pharm
December 2024
School of Pharmacy, Shenyang Key Laboratory of Intelligent Mucosal Drug Delivery Systems, Shenyang Pharmaceutical University, Shenyang 110016, China; Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education, China. Electronic address:
A commonly used strategy to improve aerosolization behavior of carrier-based dry powder inhalers (DPIs) is the addition of magnesium stearate as a lubricant, yet it may also negatively affect properties of DPIs. Thus, the aim of this study was to find lubricants that could be used as alternatives of magnesium stearate and meanwhile verify the applicability of using powder rheological properties to predict the performance of different lubricants in DPIs. Here, using fluticasone propionate as a model drug, LH200 as the carrier, influence of lubricants type and particle size, including magnesium stearate, sodium stearate, Leucine, sodium stearate fumarate, Compritol® 888 ATO, and Compritol® HD5 ATO, on the physicochemical properties, powder rheology and aerosolization behavior of the DPI formulations was characterized.
View Article and Find Full Text PDFIntravenous magnesium sulfate in pulmonary hypertension of the newborn: a systematic review.
Eur Rev Med Pharmacol Sci
August 2024
Department of Anesthesia and Intensive Care, ASP Trapani, Trapani, Italy.
Objective: Pulmonary hypertension in the newborn (PPHN) is a significant clinical condition characterized by elevated pulmonary artery pressures, leading to serious health consequences. Magnesium sulfate, known for its vasodilatory properties, has been studied for its potential benefits in managing PPHN. This systematic review evaluates the efficacy and safety of magnesium sulfate in neonates with PPHN.
View Article and Find Full Text PDFSynergistic effect of magnesium stearate and fine lactose in improving aerosolization performance of fluticasone propionate in dry powder formulation.
Int J Pharm
October 2024
School of Pharmacy, Shenyang Key Laboratory of Intelligent Mucosal Drug Delivery Systems, Shenyang Pharmaceutical University, Shenyang 110016, China; Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education, China. Electronic address:
Magnesium stearate (MgSt) and lactose fines are often used as ternary components in carrier-based dry powder inhalers (DPIs) to improve fine particle fraction (FPF), but whether they act synergistically to improve aerosolization performance of DPI formulations is currently less studied. In addition, the applicability of utilizing powder rheological parameters to predict the FPF needs to be further verified. Thus, in this study, using fluticasone propionate (FP) as a model drug, effect of lactose fines addition in 0.
View Article and Find Full Text PDFHigh-loading cannabidiol powders for inhalation.
Int J Pharm
July 2024
Advanced Drug Delivery Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, NSW 2006, Australia. Electronic address:
Article Synopsis
- * It found that using magnesium stearate improved aerosol performance and that the shape and size of the particles varied based on the type of inhaler used, with low-resistant inhalers resulting in higher throat deposition.
- * The optimal formulation was determined to be CBD powder with 5% magnesium stearate using a high-resistance inhaler, which showed promising results with the best fine particle fraction and minimal throat deposition, indicating potential for future in vivo testing.
Comparison of doses of Nebulized Magnesium sulphate as an adjuvant treatment with salbutamol in children with Status Asthmaticus.
Pak J Med Sci
January 2024
Ramsha Aziz, MBBS. Department of Pediatric Medicine, Ziauddin University, Karachi, Pakistan.
Article Synopsis
- The study aimed to compare the effectiveness of different doses of nebulized magnesium sulphate combined with Salbutamol in treating status asthmaticus in children aged 2-12 years.
- Conducted at Dr. Ziauddin University Hospital in Pakistan, the clinical trial involved 104 children, assessing asthma severity using the Pediatric Rapid Assessment Measure (PRAM) score before and after treatment.
- Results indicated significant improvements in asthma symptoms over time, with higher doses of magnesium sulphate combined with Salbutamol leading to greater reductions in PRAM scores compared to Salbutamol alone.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!